Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

HER2+ Breast Cancer Treatment Algorithm : Episode 5

Navigating Data Free HER2+ Breast Cancer Treatment

February 17, 2025
By Rohit Gosain, MD
Rahul Gosain, MD
  • Sarah Sammons, MD

Opinion
Video

Panelists discuss how, data-free navigation of HER2+ breast cancer treatment requires careful consideration of established guidelines while accounting for individual patient factors. Treatment typically follows a multimodal approach, combining targeted HER2 therapies, chemotherapy, and surgery based on clinical expertise.

EP: 1.Early-Stage HER2+ Breast Cancer Treatment

EP: 2.Locally Advanced HER2+ Breast Cancer

EP: 3.Escalating to TDM-1 Treatment Therapy

EP: 4.Approach to HER2+ Metastatic Disease Treatment

Now Viewing

EP: 5.Navigating Data Free HER2+ Breast Cancer Treatment

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

ONCOLOGY Staff
September 9th 2025
Article

1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 9th 2025
Podcast

Targeted Therapy Options for HER2+ Breast Cancer

Targeted Therapy Options for HER2+ Breast Cancer

ONCOLOGY Staff
September 9th 2025
Article

1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
September 9th 2025
Podcast

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

Russ Conroy
September 9th 2025
Article

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

Hayley Virgil
September 9th 2025
Article
Related Content

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

ONCOLOGY Staff
September 9th 2025
Article

1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 9th 2025
Podcast

Targeted Therapy Options for HER2+ Breast Cancer

Targeted Therapy Options for HER2+ Breast Cancer

ONCOLOGY Staff
September 9th 2025
Article

1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
September 9th 2025
Podcast

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

Russ Conroy
September 9th 2025
Article

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

Hayley Virgil
September 9th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.